Veverimer Is Effective for Metabolic Acidosis in CKD

Restricted access

The selective hydrochloric acid binder veverimer is a safe and efficacious treatment for metabolic acidosis in patients with CKD, according to a randomized trial report in the Lancet.

The study was a 40-week extension of a previous international industry-sponsored trial comparing veverimer with placebo for patients with CKD (estimated GFR 20–40 mL/min per 1.73 m2) and metabolic acidosis (serum bicarbonate 10–20 mmol/L). In that study (Lancet 2019; 393:1417–1427), 59% of patients in the veverimer group met a composite primary endpoint of increased sodium bicarbonate, compared with 22% of the placebo group.

In the extension

Save